<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035853</url>
  </required_header>
  <id_info>
    <org_study_id>colistin nasal cf pilot</org_study_id>
    <nct_id>NCT01035853</nct_id>
  </id_info>
  <brief_title>Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization</brief_title>
  <official_title>Sino-nasal Inhalation of Colistin Via the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Colonization of the Upper Airways With Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the nasal inhalation of Colistin is&#xD;
      effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of Pseudomonas aeruginosa in Nasal lavage fluid</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>Sino-Nasal inhalation, approximately 1 ml / day in each nostril</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subject has a confirmed diagnosis of cystic fibrosis&#xD;
&#xD;
          -  detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of&#xD;
             the lung (from day -28)&#xD;
&#xD;
          -  informed consent of the patients or parents&#xD;
&#xD;
          -  subject &gt;= 6 years&#xD;
&#xD;
          -  subject is able to comply with the inhalation procedures and nasal lavage procedures&#xD;
             scheduled in the protocol&#xD;
&#xD;
          -  women of childbearing potential are only included into the study, if they are using an&#xD;
             effective method of birth control during the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject has a critical condition defined as: forced expiratory volume at one second &lt;&#xD;
             30% and / or arterial oxygen saturation &lt; 93% without O2-substitution; need of&#xD;
             O2-substitution&#xD;
&#xD;
          -  subject had an ear, nose, and throat surgery within 3 months prior to study&#xD;
&#xD;
          -  subject shows signs of nasal bleeding&#xD;
&#xD;
          -  subject has an ear drum perforation&#xD;
&#xD;
          -  subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with&#xD;
             need of additional systemic antibiotic therapy against pseudomonas aeruginosa&#xD;
&#xD;
          -  subject is unlikely to comply with the procedures scheduled in the protocol&#xD;
&#xD;
          -  subject has a known allergic reaction to the medication&#xD;
&#xD;
          -  subject is pregnant or breastfeeding&#xD;
&#xD;
          -  subject participates in another clinical trial within 30 days prior to study entry or&#xD;
             30 days after end of the study.&#xD;
&#xD;
          -  systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the&#xD;
             inclusion and during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Mainz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Jena, Children's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Würtemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukoviszidosezentrum der Friedrich-Schiller-Universität</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-Zentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>PD Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

